Link Between Daily Cannabis Use and Schizophrenia Risk
About 18 million Americans who use cannabis every day significantly increase their risk of developing schizophrenia, a serious mental illness that can be fatal. This concerning conclusion comes from a recent report published by the Canadian Medical Association Journal, which found that individuals hospitalized due to cannabis-related issues were 14 times more likely to develop schizophrenia within three years.
Symptoms associated with this risk can be severe. They might include intense psychiatric symptoms—paranoia or panic attacks, for example—along with potential overdoses on THC, the compound responsible for the ‘high’ experience associated with cannabis. Alarmingly, researchers discovered that the risk of schizophrenia skyrocketed to 241 times higher for those experiencing cannabis-induced psychosis, a temporary mental health condition characterized by hallucinations and delusions.
The growing potency of cannabis is a significant factor here. THC levels have risen dramatically from around four percent two decades ago to about 20 percent today. Dr. Nicholas Fabiano from the University of Ottawa remarked that cannabis has changed considerably over the years.
While schizophrenia itself isn’t directly fatal, it can create life-threatening scenarios, particularly as individuals may have a heightened risk of suicide driven by severe depressive symptoms.
The new CMAJ report aggregated data from five studies on cannabis use in Canada, including one that spanned a large population of nearly 10 million people in Ontario. This extensive data helped underline the connection between cannabis-related health issues and the onset of schizophrenia.
Authors of the study cautioned that the more potent cannabis products today are directly linked to a higher risk of psychosis, especially among younger people, men, and those with a previous history of mental health issues like depression and anxiety. The report noted that approximately 0.47 percent of cannabis users experience psychotic symptoms—around one in every 200 users. However, around 76 percent of those who have symptoms lasting over 24 hours end up needing emergency assistance, significantly increasing their likelihood of developing schizophrenia.
Treatment for schizophrenia usually involves a mix of antipsychotic medications and therapy. Drugs such as risperidone and olanzapine aim to manage symptoms like hallucinations by balancing certain chemicals in the brain. Meanwhile, therapies like cognitive behavioral therapy can help patients navigate their everyday challenges while dealing with these symptoms.
For regular users who haven’t encountered mental health problems, researchers suggest that the best way to lower their risk is simply to stop using cannabis. The report also warned that continuing use following an initial psychotic episode might worsen the chances of those symptoms recurring.
Additionally, high-potency cannabis can induce severe nausea and vomiting in some users, while others might experience a rapid heart rate or chest pain—symptoms that could mimic a heart attack and necessitate urgent care. Exceeding safe dosages, especially through edibles or vaping, could lead to confusion, agitation, or loss of coordination, raising the risk of accidents.
For those with existing mental health issues, cannabis can exacerbate anxiety or depression, resulting in severe mood swings or even suicidal thoughts. The regulatory landscape around cannabis in the U.S. has been complex, with recreational use sanctioned in 24 states and Washington, D.C., while medical use is permitted in 38 states as of 2025. However, it remains a federally classified Schedule I drug, deemed highly dangerous with no recognized medical use.
In May 2024, the Biden administration proposed reclassifying cannabis to Schedule III to acknowledge its potential medical benefits, yet a scheduled hearing for January 2025 was canceled, leaving the future of this issue somewhat uncertain.
